A new review finds three small human studies of BPC-157

Researchers searched Embase, PubMed, the Cochrane Library, and ClinicalTrials.gov up to 1 June 2026 for any study that gave BPC-157 to human participants ¹. They included quantitative and qualitative studies for any indication, which is a broad net ¹. The review was registered in advance with PROSPERO, an international registry of systematic reviews, under number CRD420261406325, and its methods followed PRISMA, a standard reporting checklist ¹. Quality was assessed with a tool designed for studies that have no control group, and certainty of evidence was rated with GRADE, a standard system for judging how much confidence a body of evidence can support ¹.

The review ended with exactly three human studies, all judged to have poor methodological quality ¹. The limitation is the same across them: no control group, very small sample sizes, and serious risk of bias as described in the review ¹. Most participants improved in each study, but without a comparison group the change cannot be attributed to BPC-157 itself ¹. The three studies are summarized below ¹.

The knee pain study was retrospective, meaning researchers looked back at records after people had already received joint injections ¹. That design cannot separate the peptide effect from the passing of time or the expectation of benefit ¹. The interstitial cystitis study was also retrospective, with the same limitation ¹. The intravenous safety study was prospective, which is stronger for recording events, but it involved only two people, so it cannot show whether any effect is real ¹.

The reviewers rated the certainty of evidence as very low ¹. GRADE ratings start at lower confidence for studies without control groups, and can drop further when the evidence is imprecise or does not directly answer the question ¹. Here, the review listed serious risk of bias, indirectness, and imprecision as the reasons ¹. Risk of bias means the way the studies were designed could tilt the findings. Indirectness means the people or settings did not fully match the broad clinical question. Imprecision means the small numbers make any estimate unreliable. Because of those three issues, the review said BPC-157 should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials ¹.

This new review fits the existing pattern. Most BPC-157 evidence is still from rodent and test-tube models, not people ². Human data have been limited to small uncontrolled pilots, and no randomized controlled trial has been published ³. The study-level numbers in the new review, thirty people across three studies, match that limited base ¹. Animal research has shown controlled effects in ligament and tendon injury models, but the step from those models to a human effect size has not been made ³.

The rat studies are worth keeping in view because they use controlled designs. A rat Achilles repair study compared BPC-157 with TB-500 and found BPC-157 improved histology and collagen organization, though the maximum load to failure reached significance only for TB-500 ⁵. Rat ligament studies showed improved healing through 90 days ⁶. Those controlled animal findings are the main reason people are interested in BPC-157, but they have not been reproduced in a controlled human trial ¹. Separately, BPC-157 is not FDA-approved, and the FDA has determined it is unsafe for use in compounded products ⁷.

Several questions remain open. None of the human studies compared BPC-157 with a placebo, so it is unknown whether the reported symptom changes would have happened anyway ¹. No randomized controlled trial has been published, so no human effect size exists ³. The long-term safety in people is also unknown ³. Because BPC-157 can drive new blood vessel growth, there is an unresolved question about whether long-term use affects cancer risk ⁸. The review does not answer which route, dose, or treatment length would matter in people because the studies used different protocols and none was designed to compare them ¹.